Compare ATI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATI | ROIV |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | ATI | ROIV |
|---|---|---|
| Price | $108.99 | $21.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $105.43 | $21.94 |
| AVG Volume (30 Days) | 1.4M | ★ 6.7M |
| Earning Date | 02-03-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.88 | N/A |
| EPS | ★ 3.10 | N/A |
| Revenue | ★ $4,583,000,000.00 | $20,329,000.00 |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $8.40 | $376.94 |
| P/E Ratio | $35.13 | ★ N/A |
| Revenue Growth | ★ 7.75 | N/A |
| 52 Week Low | $39.23 | $8.73 |
| 52 Week High | $111.22 | $22.45 |
| Indicator | ATI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 71.78 | 68.21 |
| Support Level | $98.10 | $20.14 |
| Resistance Level | $111.22 | $21.48 |
| Average True Range (ATR) | 3.23 | 0.66 |
| MACD | 0.72 | -0.02 |
| Stochastic Oscillator | 87.53 | 87.12 |
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.